- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05873634
HeartShare: combinación de ómicas, fenotipado profundo y registros de salud electrónicos para subtipos de insuficiencia cardíaca y objetivos de tratamiento
Estudio de fenotipado profundo de HeartShare
HeartShare is a comprehensive study of heart failure, a common and serious medical condition which occurs when the heart is unable to keep up with the demands of the body, resulting in shortness of breath, fluid retention, and fatigue. HeartShare aims to better classify heart failure into subtypes to help develop more personalized treatments for patients, with the hope that this will improve the lives of heart failure patients. To do this, HeartShare is bringing together a large amount of data (including images, such as heart ultrasounds and MRIs and molecular data from the blood, such as genetics) from previously conducted studies and electronic health records, and is gathering new data through participants enrolled in the HeartShare Deep Phenotyping Study.
Descripción general del estudio
Estado
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Laura Alagna
- Número de teléfono: 312-695-6765
- Correo electrónico: heartsharestudy@northwestern.edui
Ubicaciones de estudio
-
-
California
-
Sacramento, California, Estados Unidos, 95817
- Reclutamiento
- University of California Davis
-
Contacto:
- Maiya Her
- Número de teléfono: 916-734-0230
-
Investigador principal:
- Nipavan Chiamvimonvat, MD
-
Sub-Investigador:
- Javier Lopez, MD
-
Sub-Investigador:
- Martin Cadeiras, MD
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Reclutamiento
- Northwestern University
-
Contacto:
- Laura Alagna
- Número de teléfono: 312-695-6765
- Correo electrónico: laura.alagna@northwesterne.du
-
Investigador principal:
- Sadiya Khan, MD
-
Investigador principal:
- Laura Rasmussen-Torvik, PhD, MPH
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Aún no reclutando
- Mass General Brigham
-
Investigador principal:
- Greg Lewis, MD
-
Contacto:
- Diane Cocca-Spofford
- Número de teléfono: 617-726-8228
- Correo electrónico: dcoccaspofford@mgh.harvard.edu
-
Sub-Investigador:
- Akshay Desai, MD, MPH
-
Sub-Investigador:
- Michael Givertz, MD
-
Sub-Investigador:
- Scott Solomon, MD
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos, 55905
- Reclutamiento
- Mayo Clinic
-
Investigador principal:
- Barry Borlaug, MD
-
Sub-Investigador:
- Margaret Redfield, MD
-
Contacto:
- Matthew Adolphsen
- Número de teléfono: 507-422-5919
- Correo electrónico: Adolphsen.Matthew@mayo.edu
-
-
North Carolina
-
Winston-Salem, North Carolina, Estados Unidos, 27157
- Aún no reclutando
- Wake Forest University
-
Contacto:
- Ben Nelson
- Número de teléfono: 336-716-6789
-
Investigador principal:
- Dalane Kitzman, MD
-
Sub-Investigador:
- Alain Bertoni, MD, MPH
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Reclutamiento
- University of Pennsylvania
-
Contacto:
- Tiffany Sharkoski
- Número de teléfono: 215-615-2354
-
Investigador principal:
- Julio Chirinos, MD, PhD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Adults over 30 years of age.
Descripción
Inclusion Criteria:
HF Inclusion Criteria (HeartShare Registry)
- Age ≥30 years.
- Prior diagnosis of HF in the EHR (any left ventricular ejection fraction).
Non-HF Group Inclusion Criteria (HeartShare Registry)
- Age ≥30 years.
- No known prior diagnosis of HF or use of loop diuretics.
- No known prior history of BNP >100 pg/ml or NTproBNP >300 pg/ml, if prior laboratory tests are available in the EHR.
HFpEF Inclusion Criteria (HeartShare Deep Phenotyping Cohort)
-
Age ≥30 years.
-
Left ventricular ejection fraction ≥50% measured by echocardiography.
-
Definition of HFpEF: signs and symptoms of HF, NYHA functional class II-IV, and at least one of the following:
- Elevated BNP (≥75 pg/ml in sinus rhythm or ≥225 pg/ml in atrial fibrillation/flutter) or NTproBNP (≥225 pg/ml in sinus rhythm or ≥675 in atrial fibrillation/flutter) at baseline. Choice of BNP or NTproBNP is based on availability at each clinical center.
- Prior HF hospitalization (primary reason for the hospitalization is HF with elevated natriuretic peptide levels [using the thresholds listed above], requiring IV diuresis for HF, or pulmonary edema or pulmonary vascular congestion on chest radiography).
- Elevated pulmonary capillary wedge pressure (PCWP) at rest (≥15 mmHg) or during exercise (≥25 mmHg for supine exercise or PCWP/cardiac output ratio ≥2 mmHg/L/min for upright exercise).
- Elevated H2FPEF score26 (≥5) or HFA-PEFF27 score (≥5).
Non-HFpEF Group Inclusion Criteria (HeartShare Deep Phenotyping Cohort)
- Age ≥30 years.
- Left ventricular ejection fraction ≥50% measured by echocardiography.
- No known prior diagnosis of HF or use of diuretics for fluid management.
- No known prior history of BNP ≥75 pg/ml or NTproBNP ≥225 pg/ml, if prior laboratory tests are available in the EHR.
- BNP <75 pg/ml or NTproBNP <225 pg/ml at the time of screening. Choice of BNP or NTproBNP is based on availability at each clinical center.
Exclusion Criteria:
Exclusion Criteria (HeartShare Registry) The following exclusion criteria apply to both HF and non-HF group participants, unless otherwise indicated.
- For non-HF group: any prior known left ventricular ejection fraction <50%.
- Prior history of solid organ transplantation.
- Prior history of mechanical circulatory support.
- Prior history of non-cardiac cirrhosis.
- Inability to provide written consent to the study.
Exclusion Criteria (HeartShare Deep Phenotyping Cohort) The following exclusion criteria apply to both HFpEF and non-HFpEF group participants, unless otherwise indicated.
-
Life expectancy estimated to be < 1 year.
-
Primary cardiomyopathy (including amyloid, hypertrophic cardiomyopathy, cardiac sarcoidosis, hemochromatosis, or other infiltrative cardiomyopathies) or pulmonary arterial hypertension (WHO Group I, III, or IV pulmonary hypertension).
-
Any prior known left ventricular ejection fraction <40%, except if this occurred only in the setting of an acute tachycardia episode (e.g., acute atrial fibrillation).
-
Clinically significant valvular heart disease defined as:
- Moderate to greater aortic stenosis, pulmonic stenosis, or tricuspid stenosis.
- Any mitral stenosis.
- Moderate or greater aortic regurgitation.
- Greater than moderate mitral regurgitation.
-
Any planned cardiac surgery or cardiac intervention in the next 3 months.
-
Alternative primary reason for symptoms of shortness of breath and exercise intolerance in HFpEF participants in the opinion of the enrolling investigator.
-
Cardiac surgery, acute coronary syndrome, percutaneous coronary intervention, stroke, transient ischemic attack, or carotid intervention in the preceding 6 months prior to enrollment.
-
Known symptomatic epicardial coronary artery disease that is not revascularized.
-
Any non-elective hospitalization in the preceding 2 weeks.
-
Prior history of solid organ transplantation.
-
Prior history of chronic infection (HIV, hepatitis C, hepatitis B, tuberculosis) unless treated and not clinically active in the opinion of the enrolling investigator.
-
Prior history of mechanical circulatory support.
-
Prior history of non-cardiac cirrhosis.
-
Estimated GFR <20 ml/min/1.73m2 or currently on dialysis.
-
Any condition that may preclude participation or adherence to the study protocol, in the opinion of the enrolling investigator.
-
Inability to provide written consent to the study.
-
Current acute decompensated heart failure.
-
Currently pregnant.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
|---|
|
HFpEF
Participants with HFpEF |
|
Non-HFpEF
Participants without HFpEF |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Número de participantes con insuficiencia cardíaca con fracción de eyección conservada (HFpEF)
Periodo de tiempo: Hasta 5 años
|
Hasta 5 años
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Sanjiv Shah, MD, Northwestern University
- Silla de estudio: Svati Shah, MD, MHS, Duke University
- Silla de estudio: Javed Butler, MPH, MBA, Baylor Scott and White Health
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- STU00217900
- U54HL160273 (Subvención/contrato del NIH de EE. UU.)
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .